U.S. Patent expands the scope of patent protection and increases the number of molecules that Enveric has the potential to develop or license for the treatment of neuropsychiatric conditions. CAMBRIDGE,…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry…
Read More
Once issued, this new U.S. Patent will expand the scope of Enveric's EVM301 patent portfolio of potential neuroplastogenic molecules for treatment of neuropsychiatric conditions. CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
Management to meet with investors and potential partners during Biotech Showcase 2026 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule…
Read More
Once issued, this new U.S. Patent will expand the scope of Enveric's EVM401 patent portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions. CAMBRIDGE, Mass. - Enveric Biosciences…
Read More
In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose range finding…
Read More
Common Stock Will Begin Trading on a Split-Adjusted Basis on October 28, 2025 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic…
Read More
New patent marks Enveric's 23rd issued U.S. patent for novel neuroplastogen molecules, increasing Enveric's intellectual property footprint and supporting the potential for pipeline expansion CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
EB-003, Enveric's lead product candidate, is protected by a different patent family that includes an issued U.S. patent and pending U.S. and international patents, all of which are separate and…
Read More
